The PEACH study is currently being continued with NIAID funding to continue the cohort, and the follow-up to the PEACH study will help us to better understand these outcomes. It will allow us to look at clinical predictions for the adverse outcomes but with more data, and it will also get subsets more, because what we’ve been able to look at so far is just the general question of whether inpatient therapy is better than outpatient therapy, and our answer in the whole cohort has to be “no.” But there may be subsets of women for whom the answer is not “no,” and we don’t know that yet because we don’t have enough data in each of those cells.